Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
Teclistamab Shows Promise for People with Heavily Pretreated Multiple MyelomaIn a small clinical trial, nearly 40% of people with multiple myeloma who were treated with the immunotherapy drug teclistamab (Tecvayli) had all signs of their cancer disappear. The trial participants had myeloma that did not respond to or came back after three or more prior treatments.
-
Study Confirms Dinutuximab Extends Life for Children with High-Risk NeuroblastomaResearchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.
-
Pembrolizumab Improves Survival in Advanced Triple-Negative Breast CancerAdding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer. In the KEYNOTE-355 trial, overall survival improved among patients whose tumors had high levels of the PD-L1 protein.
-
Ifosfamide May Be Treatment of Choice for Some People with Ewing Sarcoma, Trial ShowsNew findings from the first large, randomized clinical trial to compare chemotherapy regimens for relapsed or treatment-resistant Ewing sarcoma could help doctors and patients select treatments.
-
Enhertu Improves Survival for Metastatic “HER2-Low” Breast CancerPeople with metastatic breast cancer whose tumors had low levels of HER2 protein lived longer after treatment with trastuzumab deruxtecan (Enhertu) than those treated with standard chemotherapy, results of the DESTINY-Breast04 clinical trial show.
-
For Some Kids with Brain Cancer, Targeted Therapy Is Better than ChemoThe combination of dabrafenib (Tafinlar) and trametinib (Mekinist) shrank more brain tumors, kept the tumors at bay for longer, and caused fewer side effects than chemotherapy, trial results showed. The children all had glioma with a BRAF V600 mutation that could not be surgically removed or came back after surgery.
-
More Evidence that One HPV Vaccine Dose Protects against Cancer-Causing InfectionsOne dose of the HPV vaccine was highly effective in protecting young women against infection from high-risk HPV types, a study in Kenya found. A single dose would make HPV vaccines more accessible worldwide, reducing cervical cancer’s global burden.
-
For Early-Stage Lung Cancer, Nivolumab and Chemo before Surgery Proves EffectiveGiving people with early-stage lung cancer the immunotherapy drug nivolumab (Opdivo) and chemotherapy before surgery can substantially delay the progression or return of their cancer, a large clinical trial found.
-
Ivosidenib with Chemotherapy New Option for Some People with AMLFor some people with acute myeloid leukemia (AML) that has a mutation in the IDH1 gene, combining ivosidenib (Tibsovo) with the chemotherapy drug azacitidine may be a new treatment option, according to results from a large clinical trial.
-
Identifying Safer Ways to Look for Recurrence after Testicular Cancer SurgeryAfter surgery for early-stage, low-risk testicular cancer, it’s safe to monitor for a recurrence using MRI scans or fewer CT scans than are currently used, according to results from a large clinical trial.
-
Darolutamide Extends Survival for Some People with Metastatic Prostate CancerAdding darolutamide (Nubeqa) to ADT and docetaxel (Taxotere) can improve how long men with hormone-sensitive metastatic prostate cancer live without causing more side effects, results from the ARASENS trial show.
-
Trametinib Is a New Treatment Option for Rare Form of Ovarian CancerNew results from a large study show that trametinib (Mekinist) is an effective treatment for low-grade serous ovarian cancer. The findings are the first strong evidence that this rare type of ovarian cancer should be treated differently from other forms of the disease.
-
Durvalumab Modestly Improves Survival in Advanced Biliary Tract CancerAdding durvalumab (Imfinzi) to standard chemotherapy modestly extended how long people with advanced biliary tract cancer lived, results from the TOPAZ-1 trial show. The immunotherapy drug may now be the standard first-line therapy for this hard-to-treat cancer.
-
Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?Results from three clinical trials have found that CAR T cells may be superior to standard treatments for patients with B-cell NHL that has not responded to treatment (refractory) or has returned after treatment (relapsed).
-
When Ovarian Cancer Returns, Surgery May Be a Good Choice for Selected PatientsFor patients with recurrent ovarian cancer who meet strict criteria, additional surgery may improve survival, results from a large clinical trial show.
-
Immunotherapy Combination Most Effective as Initial Treatment for BRAF+ MelanomaClinical trial finds that ipilimumab (Yervoy) and nivolumab (Opdivo) combo is superior to a combination of the targeted therapies dabrafenib (Tafinlar) and trametinib (Mekinist) as the first treatment for metastatic BRAF-positive melanoma.
-
For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side EffectsFor older adults with advanced cancer, a geriatric assessment can help direct their treatment, a new study shows. In the study, patients whose care was guided by a geriatric assessment experienced fewer serious side effects and falls in their homes.
-
Shorter, More Intensive Radiation Safe after Surgery for Prostate CancerMany with prostate cancer can safely receive shorter, higher-dose radiation therapy after surgery, a new study has found. The approach, called HYPORT, didn’t harm patients’ quality of life compared with the standard radiation approach, trial finds.
-
Adjuvant Immunotherapy Approved for Some Patients with Lung CancerAtezolizumab (Tecentriq) is now the first immunotherapy approved by FDA for use as an additional, or adjuvant, treatment for some patients with non-small cell lung cancer. The approval was based on results of a clinical trial called IMpower010.
-
Enhertu May Be Preferred Therapy for Some Metastatic Breast CancersIn people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.